India, July 22 -- Godavari Biorefineries Limited, through its clinical-stage biotech division Sathgen Therapeutics, has been granted a patent by the China National Intellectual Property Administration (CNIPA) for its novel anti-cancer molecule, HYDROXY-1,4-NAPHTHALENEDIONE. This patent represents a significant milestone in the company's ongoing efforts to develop effective cancer treatments.
The patented molecule belongs to a new class of compounds that have shown strong inhibitory activity against cancer and cancer stem cells in laboratory studies. These compounds have demonstrated promising efficacy against several cancer types, including breast and prostate cancer, reinforcing their potential in future therapeutic applications.
Dr. San...